<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374188</url>
  </required_header>
  <id_info>
    <org_study_id>RS/19.23</org_study_id>
    <nct_id>NCT04374188</nct_id>
  </id_info>
  <brief_title>Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy</brief_title>
  <official_title>Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diaa Eldin Taha Ramadan Mohamed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kafrelsheikh University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of ciprofloxacin therapy in avoidance of sepsis in patient undergoing percutanous
      nephrolithotomy. A randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To figure out the value of oral ciprofloxacin medication in ameliorate the outcome of renal
      nephrolithiasis extraction via the endoscope as regard the sepsis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Efficacy of ciprofloxacin therapy in sepsis avoidance.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ciprofloxacin versus levofloxacin duration before PCNL</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate whether 7 days of ciprofloxacin or levofloxacin before PCNL, can reduce upper urinary tract infection and urosepsis after PCNL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences between Culture and sensitivity (C&amp;S) of Preoperative urine (MSU) and intraoperative renal pelvic urine</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the difference between C&amp;S of Preoperative urine (MSU) and intraoperative renal pelvic urine and extracted stone, in predicting the upper urinary tract infection and urosepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of systemic inflammatory response syndeome (SIRS) and sepsis post PCNL.</measure>
    <time_frame>12 months</time_frame>
    <description>assess the risk factors for SIRS and sepsis in PCNL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ciprofloxacin tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>drug adminstration to ameliorate sepsis incidence</description>
    <arm_group_label>ciprofloxacin</arm_group_label>
    <other_name>quinolones</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>levofloxacin pill</description>
    <arm_group_label>levofloxacin</arm_group_label>
    <other_name>quinolones</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patient 18 years or older

          -  Stones â‰¥ 2 cm and/or mild to moderate hydronephrosis

          -  Sterile mid urine stream

        Exclusion Criteria:

          -  Patients with a stent, nephrostomy tube or indwelling catheter

          -  Renal failure

          -  Fever before surgery

          -  Previous manipulation/procedure

          -  Concomitant bladder stone or tumour

          -  Patients with active UTI

          -  Contralateral renal/ureteric stone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diaa Eldin Taha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diaa Eldin Taha, MD</last_name>
    <phone>01008531384</phone>
    <email>drdiaaeldin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hossam Nabeeh, MD</last_name>
    <email>dr_hossam_nabeeh@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kafrelsheikh faculty of medicine</name>
      <address>
        <city>Kafr Ash Shaykh</city>
        <state>Kafrelsheikh</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diaa ELDIN Taha, MD</last_name>
      <phone>01008531384</phone>
      <email>drdiaaeldin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hossam Nabeeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kafrelsheikh University</investigator_affiliation>
    <investigator_full_name>Diaa Eldin Taha Ramadan Mohamed</investigator_full_name>
    <investigator_title>Lecturer of urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

